Loading...

HYPD HYPERION DEFI INC Investments/Divestments 8-K Filing

HYPR

HYPD

HYPERION DEFI INC

(HYPD)

2023 8-K

Show Summary

Summary

Stock Increase Approved

Quarterly Results

Debt-Equity Swaps

Merger of Equals

Notice of Delisting

Business Combination

Nasdaq Compliance

Stockholder Meeting

Warrant Repricing

Sales Agreement Update

Nasdaq Delisting Notice

Debt Restructuring

Strategic Review

Financial Results

Management Changes

Financial Results

Compliance regained with Na...

Registered Direct Offering

Capital Structure Amendment

Regulation FD Disclosure

Termination of Prospectus S...

Financial Results Announcement

Registered Direct Offering

Termination and Product Dev...

Regulation FD Disclosure

Investor Conferences

Investor Presentation

Reacquisition of Pediatric ...

Financial Results and Appoi...

Regulation FD Disclosure

License Agreement with Form...

Financial Results Announcement

Annual Meeting Approval

Regulation FD Disclosure

Financial Results and Corpo...

Financial Results and Corpo...

Resignation of Director

Collaboration Agreement

Presentation Release

External Links:

Eyenovia, Inc. entered into a license agreement with Formosa Pharmaceuticals, granting them an exclusive license to commercialize a novel formulation of Clobetasol Proprionate for ophthalmic use.

AI Assistant

HYPERION DEFI INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.